Last reviewed · How we verify
Veregen only
Veregen is a polyphenon E extract that induces apoptosis and inhibits growth of human papillomavirus (HPV)-infected cells through multiple molecular pathways.
Veregen is a polyphenon E extract that induces apoptosis and inhibits growth of human papillomavirus (HPV)-infected cells through multiple molecular pathways. Used for External genital warts (condyloma acuminata) caused by human papillomavirus.
At a glance
| Generic name | Veregen only |
|---|---|
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Botanical extract / polyphenol immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Oncology / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Veregen contains catechins and other polyphenols derived from green tea that target HPV-infected keratinocytes. The active compounds induce cell cycle arrest and programmed cell death in dysplastic cells while modulating immune responses against HPV. The exact molecular targets include potential effects on viral protein expression and cellular signaling pathways involved in HPV-driven proliferation.
Approved indications
- External genital warts (condyloma acuminata) caused by human papillomavirus
Common side effects
- Local skin irritation
- Erythema
- Pruritus
- Burning sensation
- Erosion
Key clinical trials
- Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment (NA)
- Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study (PHASE4)
- Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers (PHASE1)
- Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Veregen only CI brief — competitive landscape report
- Veregen only updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI